Beigene Ltd

Chart & Performance

D1W1MN

No data to show

P/E

—

P/S

3.36

EPS

—

Div Yield, %

—

Shrs. gr., 5y

86.67%

Rev. gr., 5y

54.83%

Revenues

3.81b

+54.96%

Net income

-645m

L-26.87%

CFO

-141m

L-87.85%

Earnings

May 06, 2025

Profile

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

URL

https://www.beigene.com/

IPO date

Feb 03, 2016

Employees

10,000

Domiciled in

Incorporated in

Valuation

Order:

Title CNY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CNY in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues	3,810,241 54.96%	2,458,779 73.65%	1,415,921 20.37%
Cost of revenue	2,547,384	2,158,514	3,567,491
Unusual Expense (Income)
NOPBT	1,262,857	300,265	(2,151,570)
NOPBT Margin	33.14%	12.21%
Operating Taxes	111,785	55,872	42,778
Tax Rate	8.85%	18.61%
NOPAT	1,151,072	244,393	(2,194,348)
Net income	(644,786) -26.87%	(881,708) -56.00%	(2,003,815) 41.78%
Dividends
Dividend yield
Proceeds from repurchase of equity		55,712	46,964
BB yield		-3.85%	-2.69%
Debt
Debt current	869,105	732,266	353,010
Long-term debt	272,614	264,070	596,675
Deferred revenue	30,324	300	80,202
Other long-term liabilities	90,697	221,172	343,600
Net debt	(1,614,624)	(2,267,708)	(3,682,382)
Cash flow
Cash from operating activities	(140,631)	(1,157,453)	(1,496,619)
CAPEX	(492,663)	(561,896)	(469,099)
Cash from investing activities	(548,350)	60,004	1,077,123
Cash from financing activities	193,449	416,478	(18,971)
FCF	853,416	(348,466)	(2,353,550)
Balance
Cash	2,627,410	3,174,400	4,540,288
Long term investments	128,933	89,644	91,779
Excess cash	2,565,831	3,141,105	4,561,271
Stockholders' equity	(8,755,686)	(8,061,361)	(7,157,624)
Invested Capital	13,288,795	12,772,295	12,811,904
ROIC	8.83%	1.91%
ROCE	27.60%	6.35%
EV
Common stock shares outstanding	1,361,083	104,387	103,133
Price	14.21 2.41%	13.87 -18.00%	16.92 -18.82%
Market cap	19,338,889 1,235.33%	1,448,253 -17.00%	1,744,852 -9.77%
EV	17,724,265	(819,455)	(1,937,530)
EBITDA	1,434,619	387,940	(2,085,292)
EV/EBITDA	12.35		0.93
Interest			52,480
Interest/NOPBT